A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.

Also called NCT01584232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 361 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01584232
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01584232. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2014-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY2189265
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Sulfonylureas (SU)
Intervention (Drug)
Biguanide (BG)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01584232
Content hash
bc07b0fcd2fcd771c6a0be92a33fd8681717eadf6afec4b9f8b3fe7a3d1f2f65